Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers

M Rayoo; M Yan; EA Takano; GJ Bates; PJ Brown; AH Banham; SB Fox

Journal article

Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers

M Rayoo, M Yan, EA Takano, GJ Bates, PJ Brown, AH Banham, SB Fox

Journal of Clinical Pathology | BMJ PUBLISHING GROUP | Published : 2009

DOI: 10.1136/jcp.2009.065169

Abstract

Background: The role of FOXP1 in sporadic breast cancers has been widely studied but its role in familial breast cancers is yet unexplored. Aims: To investigate FOXP1 expression in different molecular subtypes of familial breast cancers and to correlate its expression with clinicopathological parameters, oestrogen receptors (ER) and survival. Methods: Immunohistochemical staining for FOXP1 was performed in 126 familial breast carcinomas comprising 35 BRCA1, 34 BRCA2 and 57 BRCAX. Results: Nuclear FOXP1 expression ranged from focal weak to widespread strong expression. Expression of FOXP1 was higher in familial breast cancers (54%) compared with sporadic cancers (46%) (p,0.001). There was a s..

View full abstract

University of Melbourne Researchers

Stephen Fox Author

Related Projects (2)

RISK FACTORS, SCREENING, PROPHYLAXIS AND OUTCOMES IN INDIVIDUALS FROM BREAST CANCER FAMILIES: KCONFAB FOLLOW-UP STUDY

Having a strong family history of breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2,..

How can the risk of breast cancer be reduced in those with a strong family history of the disease?

Having a strong family history for breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2..

Grants

Awarded by NHMRC

Funding Acknowledgements

[ "We wish to thank Heather Thorne, Eveline Niedermayr, kConFab, the Family Cancer Clinics, and the Clinical Follow up Study ( funded by NHMRC grants 145684, 288704 and 454508), and the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC), and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia.", "This study was partly funded by the Victorian Breast Research Consortium and the Victorian Cancer Biobank, Australia." ]